Literature DB >> 25591816

Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China.

Huiqing Shi1,2, Fengjun Sun3, Jianhong Chen4, Qianyi Ou5, Wei Feng6, Xiaolan Yong7, Peiyuan Xia8.   

Abstract

BACKGROUND: Escherichia coli is one of the most common clinical pathogens causing nosocomial infection. The widespread cefotaxime-beta lactamases (CTX) has increased the multidrug resistance (MDR) of E. coli and has brought great trouble to the doctor treating the infection.
METHODS: ESBL-positive E. coli isolates were collected from different hospitals in different areas and the minimal inhibitory concentration (MIC) was analyzed by the agar dilution method. The resistance gene types were detected using polymerase chain reaction (PCR) and the sequence types were determined by multilocus sequence typing (MLST).
RESULTS: We found that the blaCTX-M-1 group and the blaCTX-M-9 group were the main CTX-M gene types, with many kinds of MLST gene types. Except for TEM with high isolate, SHV, OXA and VEB were relatively rare, while no PER and GES was detected. Most strains may have other resistance mechanisms, and the ESBL positive strains have high resistance not only to cephalosporins but also to other kinds of antibiotics.
CONCLUSION: The study provides wide epidemiological data and enables more effective infection control and treatment plans.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25591816      PMCID: PMC4299296          DOI: 10.1186/s12941-015-0063-7

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   3.944


Introduction

Escherichia coli is one of the most common clinical pathogens causing nosocomial infection. For a long time, the widespread use of antibiotics to treat E. coli infectious disease has rapidly increased the multidrug resistance (MDR) of E. coli and hence has brought great trouble to the doctor treating the infection [1,2], especially with those strains producing extended-spectrum β-lactamase (ESBL). Although the Clinical and Laboratory Standards Institute (CLSI) reduced the necessity of ESBL screening and confirmatory tests and routine ESBL testing was no longer necessary in determining the dosage of antibiotics, ESBL testing is still useful for epidemiological purposes, because the ESBL-resistance gene carries a plasmid and transmits rapidly. After SHV-1 and TEM-1, the ESBL family of cefotaxime-beta lactamases (CTX) has been reported in the literature to be increasing in frequency around the world [3,4]. CTX-M-β-lactamases can be divided into five groups according to their amino acid sequence identities. Different CTX genotypes have different hydrolysis reactions to β-lactam antibiotics [5,6]. Obtaining accurate and prompt epidemiological data from CTX-M and other ESBL positive E. coli infections can enable an effective empirical therapy plan and infection control program. However, there has been little research in this area in China. In this study, we collected ESBL-positive E. coli from -different hospitals in different areas and analyzed the CTX-M and other ESBL gene type strains in China.

Materials and methods

Bacterial strains

A total of 342 isolated strains were collected from five general teaching hospitals in Chongqing, Henan, Tianjin, Hainan and Hebei from January 2012 to December 2013. Only samples collected from infectedsites of inpatients of more than 48 h were included in the study. The sources of the clinical specimens were as follows: urine (107), sputum (65), blood (52), pus (34), abdominal fluid (22), bile (15), wound (12), skin (9), pleural fluid (6), vagina (5), joint (5), catheter (4), cerebrospinal fluid (3), drainage liquid (2) and paracentesis fluid (1). The isolated strains were tested using biochemical assays, the Vitek system (bioMe’rieux Vitek) and conventional biochemical and growth methods. The presence of ESBLs was evaluated in both the control strains and the recent clinical isolates. Double-disk diffusion was used to detect ESBL production. The cefotaxime (CTX) and ceftazidime (CAZ) disks in combination with clavulanate (CLA) were performed and interpreted by CLSI criteria for ESBL screening and disk confirmation tests [7]. Klebsiella pneumoniae ATCC 700603 and E. coli ATCC 25922 were used as positive and negative controls, respectively. The non-repeated ESBL positive E. coli were collected, and all the strains were collected from different patients.

Antimicrobial susceptibility

Antimicrobial susceptibility to a variety of drugs (including ampicillin, piperacillin, cefotaxime, cefepime, cefuroxime, cefoxitin, ceftazidime, aztreonam, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin, amikacin, amoxicillin/clavulanic acid, ampicillin/sulbactam, piperacillin/tazobactam and trimethoprim-sulfamethoxazole) was evaluated by the agar dilution method according to CLSI guidelines (CLSI, 2014). E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality control strains.

Molecular detection of ESBL

All the isolates were screened by PCR using the specific primers for each couple primer in Table 1 [8,9]. The PCR products were sent for DNA sequencing and the sequence results were analyzed using the NCBI BLAST program (http://www.ncbi.nlm.nih.gov/).
Table 1

Primers used to amplify ESBL resistance genes

Target(s) Sequence
CTX-M group Ia GACGATGTCACTGGCTGAGC
AGCCGCCGACGCTAATACA
CTX-M group IIb GCGACCTGGTTAACTACAATCC
CGGTAGTATTGCCCTTAAGCC
CTX-M group IIIc CGCTTTGCCATGTGCAGCACC
GCTCAGTACGATCGAGCC
CTX-M group IVd GCTGGAGAAAAGCAGCGGAG
GTAAGCTGACGCAACGTCTG
CTX-M group Ve GCACGATGACATTCGGG
AACCCACGATGTGGGTAGC
TEMCATTTCCGTGTCGCCCTTATTC
CGTTCATCCATAGTTGCCTGAC
SHVAGCCGCTTGAGCAAATTAAAC
ATCCCGCAGATAAATCACCAC
OXAf GGCACCAGATTCAACTTTCAAG
GACCCCAAGTTTCCTGTAAGTG
VEBCATTTCCCGATGCAAAGCGT
CGAAGTTTCTTTGGACTCTG
PERGCTCCGATAATGAAAGCGT
TTCGGCTTGACTCGGCTGA
GESAGTCGGCTAGACCGGAAAG
TTTGTCCGTGCTCAGGAT

aCTX-M-1, −3, −10 to −12, −15 (UOE-1), −22, −23, −28, −29, and −30.

bCTX-M-2, −4 to −7, and −20 and Toho-1.

cCTX-M-8.

dCTX-M-9, −13, −14, −16 to −19 and −21, and −27 and Toho-2.

eCTX-M-25 and −26.

fOXA-1.

Primers used to amplify ESBL resistance genes aCTX-M-1, −3, −10 to −12, −15 (UOE-1), −22, −23, −28, −29, and −30. bCTX-M-2, −4 to −7, and −20 and Toho-1. cCTX-M-8. dCTX-M-9, −13, −14, −16 to −19 and −21, and −27 and Toho-2. eCTX-M-25 and −26. fOXA-1.

MLST analysis

Multilocus sequence typing (MLST) was performed for the E. coli isolates [8]. The primers of seven housekeeping genes, including adk, fumC, gyrB, icd, mdh, purA and recA, were PCR-amplified, purified and sequenced. The sequences were then compared with the PubMLST database http://mlst.warwick.ac.uk/mlst/dbs/Ecoli), and each unique combination of alleles (the allelic profile) was designated as a sequence type (ST) [10].

Statistical analysis

The qualitative variables of the resistance rate to antimicrobial agents were compared using the chi-square test or the Fisher’s exact test with SPSS 10.0 software package. P ≤ 0.05 was considered statistically significant.

Results

During the study period, we obtained 130 ESBL-producing strains from clinical specimens. Among the strains, 21 were from Hebei, 19 from Hainan, 30 from Henan, 30 from Tianjin and 30 from Chongqing. The sources of the clinical specimens were as follows: − urine (36), blood (21), sputum (20), pus (18), abdominal fluid (10), bile (8), wound (7), skin (5), vagina (2), pleural fluid (2) and joint (1). The resistance rate of ESBL-producing E. coli from different areas is presented in Table 2. The ESBL positive strains were highly resistant to cephalosporins and fluoroquinolones. However, the strains responded better to the enzyme inhibitor and β-lactam antibiotics. Only three strains were resistant to imipenem, and two were resistant to meropenem. The cephalosporins and fluoroquinolones resistance rate of isolated strains from Hainan was lower than that of the strains from the other hospitals.
Table 2

Antimicrobial susceptibility of ESBL-producing isolates from different areas

Antimicrobial agent Hainan (n = 19) Hebei (n = 21) Chongqing (n = 30) Henan (n = 30) Tianjin (n = 30)
Ampicillin100100100100100
Piperacillin10010010010093.3
Cefotaxime94.710010010090
Cefepime68.495.2*93.39083.3
Cefuroxime10010010010096.7
Cefoxitin15.823.836.716.720
Ceftazidime26.361.9*56.7*63.3*53.3
Aztreonam5.361.9**73.3**76.7**60**
Imipenem003.36.70
Meropenem006.700
Amoxicillin/Clavulanic acid84.29.5**43.3**50*20**
Ampicillin/Sulbactam73.771.48083.376.7
Piperacillin/Tazobactam5.3023.33.36.7
Trimethoprim-sulfamethoxazole78.985.783.383.373.3
Ciprofloxacin68.490.57076.760
Levofloxacin47.490.5**7076.7*60
Amikacin5.3016.76.76.7
Gentamycin52.685.7*63.366.776.7

**P < 0.01 and *P < 0.05.

Antimicrobial susceptibility of ESBL-producing isolates from different areas **P < 0.01 and *P < 0.05. There were 126 (96.9%) ESBL-producing isolates of amplified blaCTX-M genes, while only four strains were CTX-M negative. The positive rate of the ESBL resistance genes from different areas is presented in Table 3. The blaCTX-M-1 group and the blaCTX-M-9 group were detected at 66.9% (87/130) and 54.6% (71/130), respectively. No blaCTX-M-2, blaCTX-M-8, and blaCTX-M-25 groups were detected in the isolates. The blaCTX-M-9 group had CTX-M-65 and CTX-M-14. The blaCTX-M-1 group had CTX-M-3 and CTX-M-15. There were 110 (84.6%) strains of amplified TEM. The OXA and SHV genes were detected at 21.5% (28/130) and 17.7% (23/130), respectively. Only 7 isolates were VEB positive. Neither PER nor GES was detected in the strains. Most strains had more than two resistance genes.
Table 3

Distribution of ESBL resistance genes in different areas

Hainan (n = 19) Hebei (n = 21) Chongqing (n = 30) Henan (n = 30) Tianjin (n = 30)
blaCTX-M-1 group57.9(11)42.9(9)83.3(25)83.3(25)56.7(17)
blaCTX-M-9 group68.4(13)71.4(15)53.3(16)26.7(8)63.3(19)
TEM63.2(12)85.7(18)96.7(29)83.3(25)86.7(26)
SHV0(0)14.3(3)30.0(9)13.3(4)23.3(7)
OXA10.5(2)33.3(7)26.7(8)16.7(5)20.0(6)
VEB0(0)0(0)16.7(5)0(0)6.7(2)
Distribution of ESBL resistance genes in different areas MLST results showed that 130 isolated strains had 42 gene types. The ST131 and ST167 were the most common genotypes with 19 and 12 strains separately. ST38, ST10, ST405 and ST2003 were less common with 9, 7, 7, and 6 isolates separately. For others, there were two genotypes having 5 strains, three having 4 strains, four having 3 strains, 9 having 2 strains and 18 having only 1 strain.

Discussion

This study presented the epidemiology of CTX-M E. coli from five hospitals in different cities of China. The results showed that the ESBL-producing isolates were highly resistant to both the cephalosporins and the fluoroquinolones confirming other reports [8,11]. This suggests that the ESBL resistance gene may exist with other resistance genes. Hence cephalosporin and fluoroquinolone are not considered to be effective choices for treatment of patients with ESBL-producing Enterobacteriaceae infection because of their relatively high resistance rates. However, the resistance rates of ceftazidime and aztreonam from Hainan hospital were lower than those from the other hospitals and other reports [8,12,13]. This demonstrates that other resistance mechanisms exist along with the ESBL in most strains. In our study, only four carbapenem-resistant strains were detected, so carbapenems were recommended as reserve antimicrobials to treat ESBL bacterial infections. Though the five hospitals were widely separated in China, the resistance rate of clinical isolates from the hospitals to the tested drugs was similar except the strains from Hainan, which showed that the ESBL-producing strains had a similar drug resistance spectrum. All ESBL-positive strains from the five hospitals were analyzed for blaCTX-M genes by PCR assay. The results showed that almost all isolates (126/130) - carried blaCTX-M. Obviously, the blaCTX-M type is the most common ESBL resistance gene in China, as most reports indicate. The CTX-M ESBL E. coli positive rate is higher than that reported abroad [8,14,15], which is due to the wide use of - β-lactam antibiotics. At the same time, the main CTX-M gene types of the five cities were CTX-M-14 and CTX-M-15, which is confirmed by most research in China [8,16]. At the same time, the positive rates of the blaCTX-M-1 group and the blaCTX-M-9 group have some differences, which suggest that there are regional epidemiological characteristics. This result suggests that CTX-M-14 is widely distributed among hospital infection patients, and that when doctors doubt whether ESBL E. coli infection is present, they try to avoid using the β-lactam antibiotics. The β-lactam/β-lactamase inhibitor combinations, carbapenems and amikacin should first be considered. The results for the TEM, SHV, OXA, VEB, PER and GES genes assay showed that TEM-positive E coli strains were also very common in the five hospitals, while the others were relatively rare, which was consistent with the results in previous studies [17,18]. At the same time, the positive rates of the TEM, SHV, OXA and VEB gene have some differences among areas, indicating that there are some regional epidemiological characteristics. The study showed that the CTX-M-type ESBL was the most common resistance gene type. As the different ESBL resistance genes have different hydrolysis capabilities with differentβ-lactams antibacterials, so the different ESBL distributions should be considered in antibacterial use. All the clinically isolated strains belonged to 42 gene types. ST131 was the most common with 19 strains, which was confirmed by domestic and international research [8,19-21]. ST167 was the second with 12 strains. ST167 was also a common genotype in E coli in foreign research [22], which was seldom reported in China [23]. ST167 was listed a lineage with a potential extended host spectrum genotype. Except for ST131 and ST167, no other types had more than 10 strains. There was no obvious relationship between the MLST gene type and ESBL resistance gene type. This result suggests that the ESBL gene is widely distributed in different MLST gene types, which is confirmed by other reports. This research has two limitations: first, the clinical information was not acquired, and we could not further analyze the risk factors for ESBL E. coli infections; second, the number of strains was not large enough to display epidemiological features. Generally speaking, the study examined the drug resistance and genotypic epidemiology of CTX-M type clinically isolated E. coli. We found that the CTX-M is still the primary genotype of ESBL in China, and that the ESBL positive strains have higher resistance. The CTX-M-14 and CTX-M-15 are the most common resistance gene types and ST131 is the predominant clonal group. This study will provide reference data to enable relevant infection control and treatment.
  22 in total

Review 1.  Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.

Authors:  R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp.

Authors:  Johann D D Pitout; Ashfaque Hossain; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

Review 4.  Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.

Authors:  Enrico Maria Trecarichi; Roberto Cauda; Mario Tumbarello
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

Review 5.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  CTX-M-type β-lactamases: a successful story of antibiotic resistance.

Authors:  Marco Maria D'Andrea; Fabio Arena; Lucia Pallecchi; Gian Maria Rossolini
Journal:  Int J Med Microbiol       Date:  2013-03-13       Impact factor: 3.473

7.  Analysis of extended-spectrum-β-lactamase-producing Escherichia coli isolates collected in the GERM-Vet monitoring programme.

Authors:  Anne-Kathrin Schink; Kristina Kadlec; Heike Kaspar; Joachim Mankertz; Stefan Schwarz
Journal:  J Antimicrob Chemother       Date:  2013-04-18       Impact factor: 5.790

8.  Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Authors:  Kayoko Hayakawa; Sureka Gattu; Dror Marchaim; Ashish Bhargava; Mohan Palla; Khaled Alshabani; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Pranathi Rao Sundaragiri; Moumita Sarkar; Hari Kakarlapudi; Balaji Ramasamy; Priyanka Nanjireddy; Shah Mohin; Meenakshi Dasagi; Satya Datla; Vamsi Kuchipudi; Swetha Reddy; Shobha Shahani; Vijaya Upputuri; Satya Marrey; Vedavyas Gannamani; Nandhini Madhanagopal; Srinadh Annangi; Busani Sudha; Kalyan Srinivas Muppavarapu; Judy A Moshos; Paul R Lephart; Jason M Pogue; Karen Bush; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

9.  Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15.

Authors:  Sun Hee Park; Ji-Hyun Byun; Su-Mi Choi; Dong-Gun Lee; Si-Hyun Kim; Jae-Cheol Kwon; Chulmin Park; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  BMC Infect Dis       Date:  2012-06-29       Impact factor: 3.090

10.  Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates.

Authors:  Marie-Hélène Nicolas-Chanoine; Jérôme Robert; Marie Vigan; Cédric Laouénan; Sylvain Brisse; France Mentré; Vincent Jarlier
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

View more
  9 in total

1.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

2.  Rapid rise of the ESBL and mcr-1 genes in Escherichia coli of chicken origin in China, 2008-2014.

Authors:  Congming Wu; Yingchao Wang; Xiaomin Shi; Shuang Wang; Hongwei Ren; Zhangqi Shen; Yang Wang; Juchun Lin; Shaolin Wang
Journal:  Emerg Microbes Infect       Date:  2018-03-14       Impact factor: 7.163

3.  Characterization of Beta-Lactamases in Bloodstream-Infection Escherichia coli: Dissemination of blaADC - 162 and blaCMY- 2 Among Bacteria via an IncF Plasmid.

Authors:  Linlin Xiao; Xiaotong Wang; Nana Kong; Long Zhang; Mei Cao; Muzhen Sun; Quhao Wei; Weiwei Liu
Journal:  Front Microbiol       Date:  2019-10-01       Impact factor: 5.640

4.  Extended-spectrum β-lactamase-producing Escherichia coli isolated from healthy Thoroughbred racehorses in Japan.

Authors:  Eddy Sukmawinata; Wataru Sato; Shuya Mitoma; Takuya Kanda; Kanichi Kusano; Yoshinori Kambayashi; Takashi Sato; Yuhiro Ishikawa; Yoshitaka Goto; Ryoko Uemura; Masuo Sueyoshi
Journal:  J Equine Sci       Date:  2019-10-02

5.  The occurrence of CTX-M-producing E. coli in the broiler parent stock in Korea.

Authors:  Kwang Won Seo; Young Ju Lee
Journal:  Poult Sci       Date:  2020-09-12       Impact factor: 3.352

6.  CTX-M-type ESBL-mediated resistance to third-generation cephalosporins and conjugative transfer of resistance in Gram-negative bacteria isolated from hospitals in Tamil Nadu, India.

Authors:  Ramesh Nachimuthu; Velu Rajesh Kannan; Bulent Bozdogan; Vaithilingam Krishnakumar; Karutha Pandian S; Prasanth Manohar
Journal:  Access Microbiol       Date:  2020-06-11

7.  Faecal carriage of CTX-M extended-spectrum beta-lactamase-producing Enterobacteriaceae among street children dwelling in Mwanza city, Tanzania.

Authors:  Nyambura Moremi; Heike Claus; Ulrich Vogel; Stephen E Mshana
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

8.  Molecular characterization, antimicrobial resistance and clinico-bioinformatics approaches to address the problem of extended-spectrum β-lactamase-producing Escherichia coli in western Saudi Arabia.

Authors:  Muhammad Yasir; Abeer M Ajlan; Shazi Shakil; Asif A Jiman-Fatani; Saad B Almasaudi; Muhammad Farman; Zainah M Baazeem; Rnda Baabdullah; Maha Alawi; Nabeela Al-Abdullah; Nashat A Ismaeel; Hani A Shukri; Esam I Azhar
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

9.  Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.

Authors:  Ahmed Zeynudin; Michael Pritsch; Sören Schubert; Maxim Messerer; Gabriele Liegl; Michael Hoelscher; Tefara Belachew; Andreas Wieser
Journal:  BMC Infect Dis       Date:  2018-10-20       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.